Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. All Antabio programs address WHO critical priority pathogens and are eligible for streamlined development. Antabio has built a best in class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and Astra Zeneca. Antabio’s lead program MBLI (expected to enter the clinic in 2020) addresses a critical global threat that is already highly prevalent in Asia-Pacific. The company is targeting strategic partnerships in Asia-Pacific to maximize its peak sales potential. Antabio has raised over €18m in non-dilutive financing to date from Wellcome Trust (2 SDD awards, 2013 and 2015) and CARB-X (2017).  The company also completed a €12,5m series A round in 2017 with second closing in 2018.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.